mRNA therapy for myocardial infarction: A review of targets and delivery vehicles
Authors:
Open Access
- 25 November 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 1037051
Abstract
Cardiovascular diseases are the leading cause of death in the world. This is partly due to the low regenerative capacity of adult hearts. mRNA therapy is a promising approach under development for cardiac diseases. In mRNA therapy, expression of the target protein is modulated by delivering synthetic mRNA. mRNA therapy benefits cardiac regeneration by increasing cardiomyocyte proliferation, reducing fibrosis, and promoting angiogenesis. Because mRNA is translated in the cytoplasm, the delivery efficiency of mRNA into the cytoplasm and nucleus significantly affects its therapeutic efficacy. To improve delivery efficiency, non-viral vehicles such as lipid nanoparticles have been developed. Non-viral vehicles can protect mRNA from enzymatic degradation and facilitate the cellular internalization of mRNA. In addition to non-viral vehicles, viral vectors have been designed to deliver mRNA templates into cardiac cells. This article reviews lipid nanoparticles, polymer nanoparticles, and viral vectors that have been utilized to deliver mRNA into the heart. Because of the growing interest in lipid nanoparticles, recent advances in lipid nanoparticles designed for cardiac mRNA delivery are discussed. Besides, potential targets of mRNA therapy for myocardial infarction are discussed. Gene therapies that have been investigated in patients with cardiac diseases are analyzed. Reviewing mRNA therapy from a clinically relevant perspective can reveal needs for future investigations.Keywords
Funding Information
- Ruijin Hospital (RC20220018)
This publication has 210 references indexed in Scilit:
- AAV Vectors for Cardiac Gene Transfer: Experimental Tools and Clinical OpportunitiesMolecular Therapy, 2011
- Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardiumBiomaterials, 2011
- Elimination Pathways of Systemically Delivered siRNAMolecular Therapy, 2011
- Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNACell Stem Cell, 2010
- Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer TherapyMolecular Therapy, 2010
- Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based MechanismsMolecular Therapy, 2010
- Lentiviral Vectors in Gene Therapy: Their Current Status and Future PotentialArchivum Immunologiae et Therapiae Experimentalis, 2010
- Cellular Uptake of Cationic Polymer-DNA Complexes Via Caveolae Plays a Pivotal Role in Gene Transfection in COS-7 CellsPharmaceutical Research, 2007
- The highways and byways of mRNA decayNature Reviews Molecular Cell Biology, 2007
- Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8Molecular Therapy, 2006